Hemonitor measures blood flow in the main artery of intensive care patients.
Hemonitor cofounder and CEO Tom Mayblum says, “Our device is small, and is attached as a patch below the side of the neck. There is no need for the doctor or medical technician who looks for a special angle in a manual ultrasound. It does this automatically. Using a smart algorithm, it is able to identify the blood flow parameters by itself.”
According to Toume, attempts were made to replace the invasive catheter with less invasive technology, but all of them use indirect measurements; they do not measure the blood flow in the main artery. One example is technologies based on bio-impedance – the body’s conductivity. “There are a number of such companies, including Israeli ones, and these products are being used, mainly in Europe, but with rather limited success,” he says. “From our understanding of the problem and a check we did at various departments in hospitals, it appears that these tests haven’t really caught on.”
Mayblum: “Our product will make it possible to expand the number of monitored patients and lower costs, compared with catheters.”
Hemonitor’s product purports to be accurate enough to become a proper replacement for a catheter, while still costing less and being less invasive. The product won the Technion Biztech competition, after which it came into contact with the incubator. According to MindUP CEO Dan Shwarzman, one of Hemonitor’s advantages is the possibility of working relatively early on a pilot with the Rambam Health Care Campus in order to verify that the product really meets the doctors’ expectations.
Shwarzman says that MindUP will support digital medical ventures, with an emphasis on preventative medicine, monitoring and personalized medical treatment, and making medical services accessible in developing countries.
Published by Globes [online], Israel Business News – www.globes-online.com – on February 22, 2017
© Copyright of Globes Publisher Itonut (1983) Ltd. 2017